Bian Yi, Xu Tingting, Le Yue, Li Shusheng
Department of Emergency Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Pharmacol. 2022 Mar 30;13:829394. doi: 10.3389/fphar.2022.829394. eCollection 2022.
Sodium bicarbonate Ringer's solution has been widely used in clinical practice in recent years. There are few clinical studies on the efficacy and safety of this fluid among critically ill patients until now. This retrospective cohort study included critically ill adult patients in the intensive care unit (ICU) of Tongji Hospital from 1 January 2019 to 31 December 2020. By reviewing exclusively the use of either sodium bicarbonate Ringer's solution or saline for resuscitation or maintenance, the patients were included into two groups, respectively. The primary outcome was the major adverse kidney event within 30 days (MAKE30), including death, new receipt of renal replacement therapy, or persistent renal dysfunction. Safety outcomes were focused on arterial blood gas and plasma biochemical alterations, which might potentially be induced by the administration of bicarbonate Ringer's solution. A total of 662 patients were included in the cohort. Compared to the saline group, the bicarbonate Ringer's group had a significantly lower rate of the new receipt of renal replacement therapy [adjusted odds ratio (OR) = 0.591, 95% confidence interval (CI), 0.406 to 0.861; = 0.006]. There was no significant difference between the two groups in 30-day mortality, final creatinine level ≥200% of baseline, and major adverse kidney event within 30 days. In subgroup analysis, the incidence of MAKE30 was higher in the bicarbonate Ringer's group than that of the saline group among patients with cardiovascular disease. The patients in the bicarbonate Ringer's group had a longer length of intensive care unit stay than patients in the saline group, but their new renal replacement therapy days were shorter. No major alterations were found in arterial blood gas and plasma biochemical during the follow-up period. Compared to saline, sodium bicarbonate Ringer's solution exhibited a potential renal function protective effect while causing no major alterations in arterial blood gas and plasma biochemistry. However, the application in patients with cardiovascular disease diagnosis at ICU admission should be cautious.
近年来,碳酸氢钠林格液已在临床实践中广泛应用。迄今为止,关于该液体在重症患者中的疗效和安全性的临床研究较少。这项回顾性队列研究纳入了2019年1月1日至2020年12月31日在同济医院重症监护病房(ICU)的成年重症患者。通过专门回顾碳酸氢钠林格液或生理盐水用于复苏或维持治疗的情况,将患者分别纳入两组。主要结局是30天内的主要不良肾脏事件(MAKE30),包括死亡、开始接受新的肾脏替代治疗或持续性肾功能不全。安全性结局聚焦于动脉血气和血浆生化改变,这些改变可能由碳酸氢钠林格液的输注所诱发。该队列共纳入662例患者。与生理盐水组相比,碳酸氢钠林格液组开始接受新的肾脏替代治疗的比例显著更低[校正比值比(OR)=0.591,95%置信区间(CI)为0.406至0.861;P=0.006]。两组在30天死亡率、最终肌酐水平≥基线水平的200%以及30天内的主要不良肾脏事件方面无显著差异。在亚组分析中,心血管疾病患者中,碳酸氢钠林格液组MAKE30的发生率高于生理盐水组。碳酸氢钠林格液组患者的重症监护病房住院时间长于生理盐水组患者,但他们接受新的肾脏替代治疗的天数更短。随访期间未发现动脉血气和血浆生化有重大改变。与生理盐水相比,碳酸氢钠林格液显示出潜在的肾功能保护作用,同时未引起动脉血气和血浆生化的重大改变。然而,对于入住ICU时诊断为心血管疾病的患者应用时应谨慎。